Explore the Latest Omalizumab Tenders on Tender Impulse - Your Trusted Global Tender Website
Are you searching for the latest Omalizumab Tenders from trusted sources across the globe? Tender Impulse is the go-to tender website for businesses seeking verified, timely updates on public tenders, government tenders and business tenders.
With real-time data and smart filters, you can find the most relevant Omalizumab Tenders issued by ministries, public sector organisations and international procurement agencies - whether you're an SME or a multinational.
All-in-One Platform for Omalizumab Tenders
- Requests for Proposals (RFPs) & Quotations (RFQs)
- General Procurement Notices (GPNs) & Expressions of Interest (EOIs)
- Prequalification documents, contract awards and amendments
Why Choose Tender Impulse?
- Custom email alerts tailored to your industry.
- Global coverage across 190+ countries and every major sector.
- Instant document access - specifications, BOQs and tender forms.
- Advanced filters by country, industry, deadline, value and procurement type.
Request a free live demo today and explore thousands of Omalizumab Tenders and beyond.
5769526Germany Pharmaceutical products Abschluss nicht-exklusiver Rabattvereinbarung nach 130a Abs 8 SGB V zum Wirkstoff OmalizumabCountry: GermanyDeadline10 Aug 20266046303Germany Pharmaceutical products Abschluss eines nicht exklusiven Rabattvertrages nach 130a Abs 8 SGB V zu Arzneimitteln mit dem Wirkstoff Omalizumab ATC-Code R03DX05Country: GermanyDeadline27 Sep 20267320321Germany Pharmaceutical products Open house Arzneimittelrabattvertrge zum Wirkstoff Omalizumab ATC R03DX05Country: GermanyDeadline28 Feb 20278706420Germany Pharmaceutical products Abschluss eines nicht exklusiven Rabattvertrages nach 130a Abs 8 SGB V zu Arzneimitteln mit dem Wirkstoff Omalizumab ATC-Code R03DX05Country: GermanyDeadline27 Sep 20268721186Germany Pharmaceutical products Abschluss eines nicht exklusiven Rabattvertrages nach 130a Abs 8 SGB V zu Arzneimitteln mit dem Wirkstoff Omalizumab ATCCode R03DX05Country: GermanyDeadline27 Jun 20279011236Germany Pharmaceutical products Open house Arzneimittelrabattvertrge Omalizumab ATC R03DX05Country: GermanyDeadline03 Aug 20279129800Germany Pharmaceutical products Abschluss nicht exkl Arzneimittel-Rabattvereinb nach 130a Abs 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Omalizumab ATC-Code nach WHOCountry: GermanyDeadline30 Sep 20269505665Germany Pharmaceutical products Arzneimittel mit dem Wirkstoff Omalizumab ATC R03DX05Country: GermanyDeadline31 Aug 20279590734Germany Pharmaceutical products Open-House-Biologika-Rabattvertrge 2025-29 - OmalizumabCountry: GermanyDeadline31 Oct 202712842012Germany Pharmaceutical products Arzneimittel mit dem Wirkstoff Omalizumab ATC R03DX05Country: GermanyDeadline30 Apr 202812958740Germany Pharmaceutical products Open House Biologika Rabattvertrge 2026 - 18 OmalizumabCountry: GermanyDeadline30 Jun 202812961799Germany Pharmaceutical products Open-House-Biologika-Rabattvertrge 2025-29 - OmalizumabCountry: GermanyDeadline31 Oct 202713149208Medicines - Conclusion not excluding medicine discount agreement. according to Section 130a Paragraph 8 SGB V by means of an open house model for the active ingredient OmalizumabCountry: GermanyDeadline30 Sep 202613185739Medicines - Open house drug discount agreements OmalizumabCountry: GermanyDeadline03 Aug 202713348056Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Omalizumab, ATC L04AG08 für die Zeit 01.08.2026 - 31.07.2028Country: GermanyDeadline04 Jun 202813380412Medicines - Open house drug discount agreements OmalizumabCountry: GermanyDeadline03 Aug 202713387536Medicines - Conclusion not excluding medicine discount agreement. according to Section 130a Paragraph 8 SGB V by means of an open house model for the active ingredient OmalizumabCountry: GermanyDeadline30 Sep 202613474450Medicines - Open house drug discount agreements OmalizumabCountry: GermanyDeadline03 Aug 202713486275Medicines - Conclusion not excluding medicine discount agreement. according to Section 130a Paragraph 8 SGB V by means of an open house model for the active ingredient OmalizumabCountry: GermanyDeadline30 Sep 202613562922Medicines - Conclusion not excluding medicine discount agreement. according to Section 130a Paragraph 8 SGB V by means of an open house model for the active ingredient OmalizumabCountry: GermanyDeadline30 Sep 202613568383Medicines - Open house drug discount agreements OmalizumabCountry: GermanyDeadline03 Aug 202713687306Medicines - Conclusion not excluding medicine discount agreement. according to Section 130a Paragraph 8 SGB V by means of an open house model for the active ingredient OmalizumabCountry: GermanyDeadline30 Sep 202613687330Medicines - Open house drug discount agreements OmalizumabCountry: GermanyDeadline03 Aug 202713758449Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Omalizumab (ATC-Code nach WHO: R03DX05)Country: GermanyDeadline29 Sep 202713893809Suministro de OMALIZUMAB SUBCUTÁNEO con destino al Servicio de Farmacia del Hospital Clinico San CarlosCountry: SpainDeadline17 Aug 2026
